First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitor

• Asıl Yazarlar: Timothy Chow (Yazar), Pirouz Shamszad (Yazar), Christopher Vinnard (Yazar), Esther Yoon (Yazar), Julia Belinski (Yazar), Irene Karpenko (Yazar), Laurent Perrin (Yazar), Kristen Auwarter (Yazar), Michael Storek (Yazar), Howard Surks (Yazar), Nancy Wong (Yazar), Yehuda Z. Cohen (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Wiley, 2023-04-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract SAR445088 is an anti‐C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system and has the potential to provide clinical benefit in the treatment of complement‐mediated diseases. A phase I, first‐in‐human, double‐blind, randomiz...